Discovery of Antinociceptive α9α10 Nicotinic Acetylcholine Receptor Antagonists by Stable Receptor Expression
ACS Chemical Biology · 2024
DOI: 10.1021/acschembio.4c00330 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, 2024. Verfasst von Kyle M Kremiller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois 60612, United States. Hauptthemen laut MEDLINE: Receptors, Nicotinic, Analgesics, Nicotinic Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Chronic neuropathic pain is an increasingly prevalent societal issue that responds poorly to existing therapeutic strategies. The α9α10 nicotinic acetylcholine receptor (nAChR) has emerged as a potential target to treat neuropathic pain. However, challenges in expressing functional α9α10 nAChRs in mammalian cell lines have slowed the discovery of α9α10 ligands and studies into the relationship between α9α10 nAChRs and neuropathic pain. Here, we develop a cell line in the HEK293 background that stably expresses functional α9α10 nAChRs. By also developing cell lines expressing only α9 and α10 subunits, we identify distinct receptor pharmacology between homomeric α9 or α10 and heteromeric α9α10 nAChRs. Moreover, we demonstrate that incubation with nAChR ligands differentially regulates the expression of α9- or α10-containing nAChRs, suggesting a possible mechanism by which ligands may modify receptor composition and trafficking in α9- and α10-expressing cells. We then apply our α9α10 cell line in a screen of FDA-approved and investigational drugs to identify α9α10 ligands that provide new tools to probe α9α10 nAChR function. We demonstrate that one compound from this screen, diphenidol, possesses antinociceptive activity in a murine model of neuropathic pain. These results expand our understanding of α9α10 receptor pharmacology and provide new starting points for developing efficacious neuropathic pain treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois 60612, United States.
- Department of Anatomy and Cell Biology, College of Medicine, University of Illinois Chicago, Chicago, Illinois 60612, United States.
- Department of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, Illinois 60607, United States.
ORCID-Profile: Hirushi Gunasekara, Alison E Ondrus, Ying S Hu, Andrew P Riley
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- NHLBI NIH HHS
- NIDA NIH HHS
- National Institute on Drug Abuse
- National Institute of General Medical Sciences
- National Heart and Lung Institute
Zitieren
APA
Kremiller, K. M., Kulkarni, G. C., Harris, L. M., Gunasekara, H., Kashyap, Y., Ilktach, G., Nguyen, A., Ondrus, A. E., Hu, Y. S., Wang, Z. J., Riley, A. P., & Peters, C. J. (2024). Discovery of Antinociceptive α9α10 Nicotinic Acetylcholine Receptor Antagonists by Stable Receptor Expression. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00330
Vancouver
Kremiller KM, Kulkarni GC, Harris LM, Gunasekara H, Kashyap Y, Ilktach G, et al. Discovery of Antinociceptive α9α10 Nicotinic Acetylcholine Receptor Antagonists by Stable Receptor Expression. ACS Chemical Biology. 2024. doi:10.1021/acschembio.4c00330
BibTeX
@article{Kremiller2024,
author = {Kremiller, Kyle M and Kulkarni, Gauri C and Harris, Lauren M and Gunasekara, Hirushi and Kashyap, Yavnika and Ilktach, Giokdjen and Nguyen, Angela and Ondrus, Alison E and Hu, Ying S and Wang, Zaijie J and Riley, Andrew P and Peters, Christian J},
title = {Discovery of Antinociceptive α9α10 Nicotinic Acetylcholine Receptor Antagonists by Stable Receptor Expression},
journal = {ACS Chemical Biology},
year = {2024},
doi = {10.1021/acschembio.4c00330}
}
EUVIMED